1/n Why Your Health App Isn't a DTx (Yet): The Regulatory and Design Hurdles of Building Software That Actually Treats Disease
- Apr 6
- 2 min read
You built a sleek health app with great user engagement. But does it actually treat a medical condition like depression, anxiety, insomnia, or ADHD?
If not, you have a wellness app, not a Digital Therapeutic (DTx).
A DTx is an evidence-based health software designed to treat or alleviate a disease by delivering a proven medical intervention. It is regulated as Software as a Medical Device (SaMD).
Most wellness apps focus on habit tracking, education, or general well-being without making disease-treatment claims. This keeps them free from heavy regulatory oversight.
The Regulatory Wall
In the US, the FDA treats DTx as Class II medical devices. Clearing them usually requires the 510(k) or De Novo pathway, along with clinical evidence from randomized controlled trials showing meaningful outcomes. Human factors testing, cybersecurity, and strict labeling rules also apply.
As of early 2026, the FDA has cleared about 192 DTx products, including EndeavorRx for ADHD, Rejoyn for depression, and reSET for substance use disorders. The process is long and expensive, which is why many companies choose to remain wellness apps.
In Europe, DTx must meet the Medical Device Regulation (MDR) for CE marking.
Design Hurdles That Go Beyond Regulation
Creating a true DTx demands much more than good UX. The app must deliver structured, protocol-driven therapy, such as a full course of cognitive behavioral therapy tailored to the user’s needs, with measurable clinical progress.
Evidence generation starts early. Trials must use validated clinical endpoints, not just user feedback. Safety protocols for crisis situations, robust data security, and controlled software updates under quality systems are mandatory.
Many DTx are prescription-only, requiring integration into clinical workflows and proof of cost-effectiveness for payer reimbursement.
Why the Distinction Matters
The market is flooded with mental health apps, making it hard for users and clinicians to separate effective tools from unproven ones. True DTx can extend care, improve outcomes, and reach more patients, but only when backed by strong evidence and regulation.
How to Bridge the Gap
If you want to move toward becoming a DTx, begin with precise intended-use statements. Engage regulators early, run rigorous clinical trials, and consider partnerships with experienced pharma or biotech companies.
The Bottom Line
Your wellness app may be helpful and well-designed, but turning it into software that treats disease requires crossing a high bar of science, regulation, and disciplined development.
Most apps are not DTx yet. For those ready to invest in the journey, the reward is the chance to deliver scalable, evidence-based care as part of the future of medicine.
What path are you taking with your app? Share in the comments.
Comments